Trump's Bold Move Against Big Pharma Drug Pricing Exposed

Trump Challenges Big Pharma with New Executive Order

On May 12, 2025, President Donald J. Trump signed a groundbreaking executive order aimed at tackling the skyrocketing costs of prescription drugs in the United States. Discussed in detail on Megyn Kelly's show with guest Walter Kirn, editor-at-large for 'County Highway,' this order seeks to align U.S. drug prices with those paid by other countries. The move is seen as a direct challenge to pharmaceutical giants who have long profited from significantly higher prices in the American market compared to elsewhere. This policy underscores the administration's commitment to making healthcare more affordable for everyday Americans.

Kirn emphasized during the discussion that the disparity in drug pricing is stark, noting that other nations pay far less for the same medications. He pointed out that while Big Pharma often justifies high prices with the need for research and development funding, their profit margins remain in the billions, suggesting room for price reductions without stifling innovation.

Unexpected Allies and Industry Pushback

At around the 5:30 mark of the video, Megyn Kelly and Walter Kirn delved into an intriguing alignment between President Trump and Senator Bernie Sanders on this issue. Kirn highlighted Sanders' past statements advocating for lower drug prices, suggesting that this could be a rare point of bipartisan agreement. He urged Sanders to support this initiative, reflecting on how both leaders have historically criticized the pharmaceutical industry's pricing practices.

However, the executive order has not been without controversy. Industry analysts have expressed skepticism about its implementation, citing potential legal and logistical challenges. Kirn noted during the segment that Big Pharma wields significant influence over media and political elites, which could lead to resistance against the order. Despite this, the administration remains steadfast in its goal to prioritize American patients over corporate profits.

Broader Implications for Healthcare Costs

Moving to the discussion around the 10:15 point, Kelly and Kirn explored why drug prices in the U.S. are so much higher than in other countries. Kirn argued that other nations negotiate prices collectively, giving them leverage that the U.S. market lacks due to fragmented systems. Trump's order aims to address this by pushing for a 'most favored nation' pricing model, which would tie U.S. drug costs to the lowest prices paid by comparable countries.

This policy could potentially reduce costs for millions of Americans who struggle with the burden of expensive medications. Kirn stressed that while Big Pharma may argue against such measures, the reality is that their profits are substantial enough to absorb price adjustments. He also called for other countries to increase their contributions to drug development costs, easing the financial load on American consumers.

Public and Political Reactions

As the conversation progressed near the 15:00 mark, Kelly and Kirn touched on the public sentiment surrounding this executive order. While specific reactions were not detailed in the segment, Kirn suggested that many Americans are frustrated with the current state of healthcare costs and would likely welcome any effort to bring relief. The administration's focus on this issue aligns with a broader agenda to protect and support citizens facing economic pressures.

The executive order is part of a larger strategy by President Trump to address systemic issues within the healthcare industry. By taking on Big Pharma, the administration aims to set a precedent for fair pricing practices, ensuring that Americans are no longer disproportionately burdened by the cost of life-saving medications. This move is seen as a fulfillment of campaign promises to prioritize the needs of the American people.

Looking Ahead at Policy Impact

Towards the end of the segment around the 20:00 mark, the discussion shifted to the potential long-term effects of this policy. While immediate price drops are not guaranteed due to procedural hurdles, experts suggest that reductions of 30 to 80 percent could be possible if the order is fully implemented. The administration is prepared to navigate these challenges, focusing on tangible results for American families.

This executive order represents a significant step forward in the fight for affordable healthcare. President Trump's determination to confront powerful industries on behalf of the American public is evident, and this policy could pave the way for further reforms. As the situation develops, the nation watches closely, hopeful for relief from the crushing weight of prescription drug costs.